BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36053960)

  • 1. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
    J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Chandran M; Bilezikian JP; Lau J; Rajeev R; Yang SP; Samuel M; Parameswaran R
    Rev Endocr Metab Disord; 2022 Jun; 23(3):485-501. PubMed ID: 35041148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
    Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
    Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
    Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
    Xu J; Yang Y; Ma L; Fu P; Peng H
    Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.
    Yao L; Li J; Li M; Lin C; Hui X; Tamilselvan D; Kandi M; Sreekanta A; Makhdami N; Ali DS; Dandurand K; Yang K; Bilezikian JP; Brandi ML; Clarke BL; Mannstadt M; Rejnmark L; Khan AA; Guyatt G
    J Bone Miner Res; 2022 Dec; 37(12):2654-2662. PubMed ID: 36385517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet for the treatment of primary hyperparathyroidism.
    Dillon ML; Frazee LA
    Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
    Khan A; Grey A; Shoback D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
    Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism.
    El-Hajj Fuleihan G; Chakhtoura M; Cipriani C; Eastell R; Karonova T; Liu JM; Minisola S; Mithal A; Moreira CA; Peacock M; Schini M; Silva B; Walker M; El Zein O; Marcocci C
    J Bone Miner Res; 2022 Nov; 37(11):2330-2350. PubMed ID: 36245249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of primary hyperparathyroidism.
    Bandeira F; de Moura Nóbrega J; de Oliveira LB; Bilezikian J
    Arch Endocrinol Metab; 2022 Nov; 66(5):689-693. PubMed ID: 36382758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism.
    Marcocci C; Bollerslev J; Khan AA; Shoback DM
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3607-18. PubMed ID: 25162668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
    Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Primary Hyperparathyroidism.
    Bilezikian JP; Silverberg SJ; Bandeira F; Cetani F; Chandran M; Cusano NE; Ebeling PR; Formenti AM; Frost M; Gosnell J; Lewiecki EM; Singer FR; Gittoes N; Khan AA; Marcocci C; Rejnmark L; Ye Z; Guyatt G; Potts JT
    J Bone Miner Res; 2022 Nov; 37(11):2391-2403. PubMed ID: 36054638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.